Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Advertisement
Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Hilleman’s Shigella Vaccine Moves To Trials In Europe, Africa In ‘Big Step Forward’

India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.

 

Research & Development Clinical Trials

AAM Slams California Pay-For-Delay Ban

US off-patent industry association the AAM has blasted as unconstitutional a groundbreaking California law banning so-called ‘pay-for-delay’ deals under which brand companies pay rivals to keep generics off the market.

Regulation Legislation

Indian Growth Expected To Top A Tenth

Indian credit rating agency ICRA has forecast that the country’s pharmaceutical industry will remain on a steady 11%-13% growth path this fiscal year, underpinned by healthy domestic demand, new launches and market share gains.

Market Intelligence India

Biocon Pledges To Cut Insulin Prices

India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”

Pricing Strategies Biosimilars

Civica Rx Supplies First Drug In US

A US hospital has received shipment of the first drug to be provided under the affordable generic supply scheme launched by Civica Rx, a nationwide coalition of hospital healthcare groups dedicated to reducing medicine shortages and tackling high prices.

Strategy United States

Mylan Will Invest $1bn In India

Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.

Strategy Manufacturing
See All
Advertisement
UsernamePublicRestriction

Register